KRAS and neoplasm: The combination of multiplex iPLEX analysis and the UHS method retrieved tumor-specific KRAS mutations, which had been found in the patient tumor tissue, in plasma samples from 58.5% (62/106) of metastasis group and 16.7% (9/54) of non-metastasis group (Table 1).